Back to comparisons

Comparison

Omega-3 (DHA/EPA) vs Apigenin

FieldOmega-3 (DHA/EPA)Apigenin
Categoryneuroprotectiveneuroprotective
Dose range1000–3000mg50–100mg
Half-life24h
Onset
EvidenceEVIDENCEAEVIDENCEB
Safety●●●●●●●●●●
Legal (US)USOTCUSOTC
PubMed refs5200400

The comparison in plain English

Auto-generated from data

Omega-3 (DHA/EPA) and Apigenin are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Apigenin Flavonoid found in chamomile, parsley, and celery.

Bottom line

Omega-3 (DHA/EPA) (evidence A, safety 5/5) has a weaker evidence base than Apigenin (evidence B, safety 5/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.

Choose Omega-3 (DHA/EPA) if

Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.

Choose Apigenin if

Apigenin is the better fit when your goal aligns with its mechanism (Partial agonist at GABA-A receptors at the benzodiazepine binding site, producing mild anxiolytic and sleep-promoting effects without the dependence profile of pharmaceutical benzodiazepines) and the dose range (50–100mg) suits your protocol. Half-life is —h.

Build a stack with bothOpen builder →
Check interactionsOpen checker →